Andrés Matesanz – General Manager, ChemSwiss Mexico
Andres Matesanz, general manager of ChemSwiss Mexico, shares his views on the Mexican API industry and its regulations as well as his personal ambitions for the company’s future. You…
ChemSwiss is an innovative and dynamic company offering a variety of products to partners within the pharmaceutical, veterinary, nutraceutical & chemical industries.
Well-known for the profound knowledge of the API market and its needs, as well as for the excellent service and technical support. ChemSwiss AG in Switzerland initially represented mainly European API manufacturers before it was able to sign exclusive deals for APIs from Chinese manufacturers. Founded in January 2012 and located in Mexico City, ChemSwiss Mexico SA de CV is one of the newest members of the ChemSwiss family.
Contact details
ChemSwiss México SA de CV
Homero Núm. Ext. 136 Núm. Int. 303
Col. Polanco V Sección, Del. Miguel Hidalgo
C.P. 11560, México D.F.
MEXICO
Tel: +52 (55) 5203 3722
Website: http://www.chemswiss.com
Andres Matesanz, general manager of ChemSwiss Mexico, shares his views on the Mexican API industry and its regulations as well as his personal ambitions for the company’s future. You…
It’s been one year since you were appointed as Federal Commissioner of COFEPRIS in March 2011. What have been the biggest challenges you’ve faced within this time? The biggest challenge…
Can you tell us a little about the history of Medix and about the company itself? Medix is a 100% Mexican company created in 1956, and our major strength is…
Apotex has increased production, launched 16 new products last March, and grown significantly in the market. What would you say has been the biggest change in the market over the…
The last time we interviewed you was in 2008. Please can you tell our readers a little bit more about Liomont’s growth drivers and changes over these last four years?…
When we saw you in 2008 we had read a little bit about the major milestones in the company, how your grandfather came to Mexico in the 1950s and how…
Please can you tell our readers a little bit more about the history of Stendhal, and its major milestones along the way since its takeover in 1997? Stendhal is a…
Carlos Garcia said in December 2009 that 6-8% of Novartis’ annual revenue comes from Latin America, and that the area is “one of the main growth engines for the company”.…
Big news last year; Takeda bought Nycomed in what has been seen as a game changing acquisition for the pharma world. How have you seen this acquisition affect Nycomed’s Latin…
The Mexican government has been fairly pro-active about promoting good practice such as the new drug registration process that helped eliminate drugs from the Mexican market that didn’t fulfill regulatory…
There have been quite a few regulatory changes in the last few years such as the new drug registration process and the suppression of the local plant rule. COFEPRIS has…
This is your 3rd interview with Focus Reports. What would you say has been the biggest change that has shaped the pharmaceutical industry since we last interviewed you in 2008?…
This is your third interview with Focus Reports. In 2004 and 2008 you were Director of AMIIF, before that you were Director of ANAFAM, and now we’re delighted to be…
See our Cookie Privacy Policy Here
